
Identification of mechanism-based therapies to treat arrhythmogenic cardiomyopathy by resolving perturbations in regulatory lipid signalingAward last edited on: 4/18/2023
Sponsored Program
SBIRAwarding Agency
NIH : NHLBITotal Award Amount
$279,136Award Phase
1Solicitation Topic Code
837Principal Investigator
Irene CortespuchCompany Information
Phase I
Contract Number: 1R43HL164226-01Start Date: 7/1/2022 Completed: 12/31/2023
Phase I year
2022Phase I Amount
$279,136Public Health Relevance Statement:
PROJECT NARRATIVE/SUMMARY: Arrhythmogenic cardiomyopathy (ACM) is a heritable heart disease that can cause life-threatening arrythmias, sometimes leading to sudden death in young people, and that over time progresses to heart failure. Currently, no mechanism-based therapies are available; however, recent evidence supports that inflammation contributes to disease progression and suggests that pro-inflammatory lipid mediators, known as eicosanoids, are increased in patients with ACM. We propose to test the hypothesis that targeting eicosanoid-driven inflammation through inhibition of the soluble epoxide hydrolase (sEH) enzyme is a safe therapeutic approach that can potentially modify disease progression in patients with ACM.
Project Terms:
Implantable Defibrillators, Implantable Cardioverter-Defibrillators, Natural History, base, improved, Acute, Chronic, Solid, Clinical, Phase, Biological, biologic, Series, Cardiac Muscle Cells, Cardiocyte, Heart Muscle Cells, Heart myocyte, cardiomyocyte, Cardiac Myocytes, Disease Progression, inflammatory mediator, Inflammation Mediators, Therapeutic, Inflammatory, Life, Oral, lipid mediator, Animal Models and Related Studies, model of animal, model organism, Animal Model, Categories, Sampling, Property, Phase I Clinical Trials, Early-Stage Clinical Trials, Phase 1 Clinical Trials, phase I protocol, palliative, preventing, prevent, small molecule, Inflammatory Infiltrate, Mediator, Mediator of Activation, Mediator of activation protein, Address, Dose, Data, Grant Proposals, Applications Grants, Resolution, Small Business Innovation Research Grant, SBIR, Small Business Innovation Research, Process, Ventricular, Cardiac, burden of illness, burden of disease, disease burden, years of life lost to disability, years of life lost to disease, Heritability, healthy volunteer, therapeutic target, induced pluripotent stem cell, iPS, iPSC, iPSCs, inducible pluripotent stem cell, drug candidate, Regimen, arrhythmogenic cardiomyopathy, cardiac muscle disease, heart muscle disease, Phase Ib Clinical Trial, Phase 1b Clinical Trial, Prognosis, Affect, Analgesics, Analgesic Agents, Analgesic Drugs, Analgesic Preparation, Anodynes, Antinociceptive Agents, Antinociceptive Drugs, pain killer, pain medication, pain reliever, painkiller, inhibitor, Anti-Inflammatory Agents, Anti-Inflammatories, Anti-inflammatory, Antiinflammatories, Antiinflammatory Agents, antiinflammatory, Arachidonic Acids, Arrhythmia, Cardiac Arrhythmia, Heart Arrhythmias, Autopsy, necropsy, postmortem, Clinical Trials, Cytochrome P450, Cytochrome P-450, Cytochrome P-450 Enzyme System, Cytochrome P450 Family Gene, P450, Sudden Death, Desmosomes, Macula Adherens, Node of Bizzozero, Spot Desmosome, Disease, Disorder, Pharmacotherapy, Drug Therapy, drug treatment, Eicosanoids, Electrocardiogram, ECG, EKG, Electrocardiography, Holter Electrocardiography, Holter Monitoring, Holtmon, Enzymes, Enzyme Gene, Epoxide hydrolase, Epoxide Hydrases, Epoxide Hydratases, Equilibrium, balance, balance function, Family, Fatty Acids, Future, Glycols, diol, Goals, Heart, Heart Diseases, Cardiac Diseases, Cardiac Disorders, heart disorder, Heart failure, cardiac failure, Heart Rate, Cardiac Chronotropism, Human, Modern Man, Inflammation, Lipids, Metabolism, Intermediary Metabolism, Metabolic Processes, Muscle, Muscle Tissue, muscular, Mutation, Genetic Alteration, Genetic Change, Genetic defect, genome mutation, Persons, Patients, Pharmacokinetics, Drug Kinetics, pilot study, Pilot Projects, Sham Treatment, sham therapy, Placebos, Polyunsaturated Fatty Acids, Production, QOL, Quality of life, Risk, social role, Role, Safety, Cell Communication and Signaling, Cell Signaling, Intracellular Communication and Signaling, Signal Transduction Systems, Signaling, biological signal transduction, Signal Transduction, Testing, Time, Tissues, Body Tissues, cytokine, sudden cardiac death, Ventricular Arrhythmia
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00